![]() |
|
|
Institute of Cell Signalling, Medical School, University of Nottingham, Queen's Medical Centre, Nottingham, United Kingdom
Many clinically used drugs are G-protein-coupled receptor (GPCR) antagonists and are given long-term to prevent receptor activation by endogenous agonists. Most GPCR antagonists are considered to have little agonist efficacy of their own. However, many
antagonists do stimulate very small
2 adrenoceptor-mediated cAMP responses, but these responses become substantial at the level of cAMP response element (CRE)-gene transcription. Here, we compared the temporal characteristics of these
2 adrenoceptor-mediated cAMP and CRE-gene transcription responses with ligands of differing agonist efficacy. Within a minute, full agonists (e.g., isoprenaline) stimulated large increases in intracellular and exported cAMP. Very weak partial agonists (e.g., alprenolol) did not increase intracellular cAMP (only stimulating a small export). However, all agonists (regardless of efficacy) stimulated an increase in CRE-gene transcription after a 2-h incubation. An initial 30-min continual stimulation was required to initiate the process of CRE-gene transcription for all ligands. Longer agonist incubations resulted in larger gene transcription responses in a proportional manner for both weak and full agonists alike, and this was despite the lack of intracellular cAMP detection for the weaker ligands. Thus, the major initiator for CRE-gene transcription was not cAMP concentration or total quantity generated but a sustained turnover of intracellular cAMP and hence sustained stimulation of CREB phosphorylation. Thus, long-acting agonists and long-term treatments with very weak partial agonists (including many drugs classified previously as antagonists based on traditional second-messenger assays, e.g., several clinically used "
-blockers") may cause more substantial gene transcription than previously believed.
Address correspondence to: Prof. S. J. Hill, Institute of Cell Signaling, Queen's Medical Centre, Nottingham NG7 2UH, United Kingdom. E-Mail: stephen.hill{at}nottingham.ac.uk
This article has been cited by other articles:
![]() |
P. Mardones, J. F. Medina, and R. P. J. O. Elferink Activation of Cyclic AMP Signaling in Ae2-deficient Mouse Fibroblasts J. Biol. Chem., May 2, 2008; 283(18): 12146 - 12153. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Baker and S. J. Hill A Comparison of the Antagonist Affinities for the Gi- and Gs-Coupled States of the Human Adenosine A1-Receptor J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 218 - 228. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Baker Evidence for a Secondary State of the Human {beta}3-Adrenoceptor Mol. Pharmacol., December 1, 2005; 68(6): 1645 - 1655. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Carter and S. J. Hill Characterization of Isoprenaline- and Salmeterol-Stimulated Interactions between {beta}2-Adrenoceptors and {beta}-Arrestin 2 Using {beta}-Galactosidase Complementation in C2C12 Cells J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 839 - 848. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. H. Heijink, E. Vellenga, J. Oostendorp, J. G. R. de Monchy, D. S. Postma, and H. F. Kauffman Exposure to TARC alters {beta}2-adrenergic receptor signaling in human peripheral blood T lymphocytes Am J Physiol Lung Cell Mol Physiol, July 1, 2005; 289(1): L53 - L59. [Abstract] [Full Text] [PDF] |
||||